FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States
Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the fastest-moving area of American metabolic and longevity medicine.
MIAMI, FL, April 28th, 2026, FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 State of Peptides and GLP-1 Regulation report. The report maps how the Robert F. Kennedy Jr. Department of Health and Human Services, the FDA Center for Drug Evaluation and Research, and a pipeline of new obesity drugs from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping what Americans can legally access for weight management, metabolic health, and peptide therapy through the end of the decade.
Get the full, more detailed press rele...
